Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

Combining an immune checkpoint inhibitor with batiraxcept (AVB-S6-500), an AXL inhibitor that acts via selective binding to growth arrest-specific protein 6 (GAS6), may improve anti-tumor immunity in platinum-resistant ovarian cancer (PROC). This phase 1b trial of durvalumab in combination with esca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:iScience 2024-05, Vol.27 (5), p.109801-109801, Article 109801
Hauptverfasser: Knisely, Anne, Hinchcliff, Emily M., Gardiner, Elisabeth, Rangwala, Reshma, Lito, Kathryn, Fellman, Bryan, Yuan, Ying, Sood, Anil K., Westin, Shannon N., Lu, Karen H., Jazaeri, Amir A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Combining an immune checkpoint inhibitor with batiraxcept (AVB-S6-500), an AXL inhibitor that acts via selective binding to growth arrest-specific protein 6 (GAS6), may improve anti-tumor immunity in platinum-resistant ovarian cancer (PROC). This phase 1b trial of durvalumab in combination with escalating doses of batiraxcept enrolled patients with recurrent PROC (NCT04019288). The primary objective was to determine the toxicity profile of the combination. Eleven patients were enrolled on the trial. No dose-limiting toxicities were observed, and no objective responses were noted. Median progression free survival (PFS) was 1.81 months (95% confidence interval (CI) 1.71–2.40), and median overall survival (OS) was 4.53 months (95% CI 2.10–24.74). Batiraxcept effectively reduced serum GAS6 levels at 1-h post-treatment, resulting in trough levels below the limit of detection in all cases but one. In conclusion, the combination of batiraxcept and durvalumab was safe and tolerable but did not demonstrate anti-tumor activity in a heterogenous population of patients with recurrent PROC. [Display omitted] •No dose-limiting toxicities occurred among all patients who received study drugs•Of 11 patients who received durvalumab and batiraxcept, no responses were noted•Median progression-free and overall survival were 1.8 and 4.5 months, respectively•Batiraxcept effectively reduced serum GAS6 levels at 1-h post-treatment Gene editing; CRISPR; Gene therapy; Cystic fibrosis; CFTR
ISSN:2589-0042
2589-0042
DOI:10.1016/j.isci.2024.109801